A pilot study of Rhodiola rosea (Rhodax) for generalized anxiety disorder (GAD)
Bystritsky A, Kerwin L, Feusner JD
Published in Journal of Alternative and Complementary Medicine, Vol. 14, pp. 175-180
Methodology
Single-arm open-label pilot study; 10 adults with DSM-IV generalised anxiety disorder took 340 mg/day R. rosea extract for 10 weeks with HARS and CGI assessments.
Key Findings
Participants showed significant decreases in mean Hamilton Anxiety Rating Scale scores at endpoint (t = 3.27, p = 0.01); adverse events were generally mild, most commonly dizziness and dry mouth.
Conclusions
R. rosea produced significant improvement in GAD symptoms in this pilot, warranting controlled replication.
Limitations
Very small uncontrolled sample (n = 10) with no placebo arm; open-label design highly susceptible to expectancy effects.
Supplements Studied
Individuals treated with R. rosea showed significant decreases in mean HARS scores at endpoint (t=3.27, p=0.01).
Outcomes Measured
Individuals treated with R. rosea showed significant decreases in mean HARS scores at endpoint (t=3.27, p=0.01).
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.